Betamethasone
- Generic Name
- Betamethasone
- Brand Names
- Betaderm, Betaloan Suik, Beteflam, Celestoderm, Celestone Soluspan, Dermacinrx Therazole Pak, Diprolene, Diprosalic, Diprosone, Dovobet, Enstilar, Fucibet, Lotriderm, Lotrisone, Luxiq, Marbeta, Rivasone, Rolene, Rosone, Sernivo, Taclonex, Valisone-G, Wynzora
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 378-44-9
- Unique Ingredient Identifier
- 9842X06Q6M
- Background
Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.
- Indication
As a member of the corticosteroid family, betamethasone is indicated for the treatment of several inflammatory conditions. As topical monotherapy, betamethasone is indicated to relieve pruritic and inflammatory symptoms of corticosteroid-responsive-dermatoses. Betamethasone can be used topically in combination with a vitamin D analog such as calcipotriene to treat plaque psoriasis. The corticosteroid is also available as an injectable suspension and can be used to manage a range of inflammatory conditions including endocrine disorders, gastrointestinal disorders, and rheumatic disorders among other conditions.
- Associated Conditions
- Acute Gouty Arthritis, Adrenocortical Insufficiency, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Atopic Dermatitis, Berylliosis, Blepharitis allergic, Blepharoconjunctivitis, Bullous dermatitis herpetiformis, Bursitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Dermatomyositis (DM), Dermatosis, Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Episcleritis, External ear inflammation, Eye allergy, Hypercalcemia of Malignancy, Inflammatory Reaction of the ear, Iridocyclitis, Iritis, Itching caused by Allergies, Keloids Scars, Keratitis, Keratitis interstitial, Keratoconjunctivitis, Leukemias, Lichen Planus (LP), Lichen simplex chronicus, Lupus Erythematosus, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Nephrotic Syndrome, Ocular Inflammation, Ocular injuries, Ophthalmia, Sympathetic, Pemphigus, Plaque psoriasis of the body, Plaque psoriasis of the scalp, Polymyositis, Post Surgical Ocular Inflammation, Pruritus, Psoriasis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Psoriatic plaque, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Scleritis, Secondary thrombocytopenia, Severe Asthma, Severe Atopic Dermatitis, Skin Infections, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Verrucous Lichen Planus (LP), Acquired immune hemolytic anemia, Acute nonspecific tenosynovitis, Acute rheumatic carditis, Bacterial blepharitis, Corticosteroid-responsive dermatoses, Eczematous rash, Exfoliative erythroderma, Granuloma annulare lesions, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Allergic rhinitis, Severe Contact dermatitis, Severe Serum sickness, Severe Transfusion Reactions, Severe drug hypersensitivity reactions, Superficial ocular infections, Symptomatic Sarcoidosis, Synovitis of osteoarthritis
- Associated Therapies
- -
Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- ACO Hud Nordic AB
- Target Recruit Count
- 55
- Registration Number
- NCT00576238
- Locations
- 🇸🇪
Nacka hudmottagning, Nacka, Sweden
🇸🇪Sophiahemmet, Stockholm, Sweden
🇸🇪Läkarhuset Vällingby, Vällingby, Sweden
Evaluation of Diprospan Injection to the Knee on Rehabilitation of Patients After TKR of the Contralateral Knee
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2008-11-11
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 50
- Registration Number
- NCT00542139
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
Caesarean and Corticotherapy
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- University Hospital, Strasbourg, France
- Target Recruit Count
- 200
- Registration Number
- NCT00446953
- Locations
- 🇫🇷
Cmco-Sihcus, Schiltigheim, France
🇫🇷Le Parc Centre pour la Mère et l'Enfant, Colmar, France
🇫🇷Centre Hospitalier de Haguenau, Haguenau, France
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT00358384
- Locations
- 🇫🇷
GSK Investigational Site, Paris, France
Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 67
- Registration Number
- NCT00139256
- Locations
- 🇺🇸
Emory University affiliated newborn intensive care units, Atlanta, Georgia, United States
Repeat Antenatal Steroids Trial
- Conditions
- Complications, Pregnancy
- First Posted Date
- 2001-04-18
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- The George Washington University Biostatistics Center
- Target Recruit Count
- 486
- Registration Number
- NCT00015002
- Locations
- 🇺🇸
Northwestern University-Prentice Hospital, Chicago, Illinois, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸MCP Hahnamann, Philadelphia, Pennsylvania, United States
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Antenatal Thyrotropin-Releasing Hormone in Pregnant Women With Threatened Premature Delivery
- Conditions
- Respiratory Distress Syndrome
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 1090
- Registration Number
- NCT00004778
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.